Prothena (NASDAQ:PRTA) Earns Buy Rating from HC Wainwright
Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They ...
HC Wainwright Issues Negative Estimate for DRUG Earnings
Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a ...
H.C. Wainwright says SEC plan to dismiss suit lifts ‘major overhang’ on Coinbase
H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...
H.C. Wainwright Sticks to Its Hold Rating for Biotricity (BTCY)
H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Biotricity (BTCY – Research Report) today. The company’s shares closed yesterday ...
Hosted on MSN3d
Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will present at the H.C. Wainwright 3rd Annual ...